Hvivo signs €19.5m contract with pharma client to test RSV antiviral drug candidate

Stock market listed pharmaceutical services firm Hvivo has signed a £16.8m (€19.5m) contract with an existing pharmaceutical client.

The contract will see Hvivo test the pharmaceutical company’s respiratory syncytial virus (RSV) antiviral drug candidate using the Hvivo RSV human challenge study model.

Irish-founded Hvivo, previously known as Open Orphan, runs drug trials known as challenge studies from its London clinics.

The contract also includes the fast manufacturing of the RSV challenge agent.

hVIVO plc (formerly Open Orphan plc) is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials, providing end-to-end early clinical development services for its broad and long-standing client base of biopharma companies.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    hVIVO plc

    More articles like this

    hVIVO plc

    The future of vaccine development through human challenge trials

    Testing new treatments and vaccines often requires years, if not decades, to gather sufficient data. In response, scientists are turning to a more direct approach that involves deliberately infecting volunteers with potentially deadly pathogens. A notable

    hVIVO plc

    The impact of Clinical Trial results on medical advancements

    Clinical trials play a pivotal role in advancing the medical industry by allowing new treatments and interventions to be rigorously tested for both effectiveness and safety. Understanding how clinical trial data is used is essential to

    hVIVO plc

    Hvivo reports significant growth in earnings and revenue

    Hvivo, previously known as Open Orphan, saw a significant increase in earnings during the first six months of the year, marking a 67.6% rise. Earnings before interest, taxes, depreciation, and amortisation reached £8.7 million (€10.32 million),

    hVIVO plc

    hVIVO reports strong first half, delivering record revenues and margins

    hVIVO plc (LON:HVO), a fast-growing specialist contract research organisation (CRO) and world leader in testing infectious and respiratory disease products using human challenge clinical trials, has announced its unaudited interim results for the six-month period ended 30 June 2024.

    hVIVO plc

    hVIVO expands to cutting-edge facility in Canary Wharf

    hVIVO plc, a specialist contract research organisation (CRO), is experiencing rapid growth, establishing itself as the global leader in testing vaccines and therapeutics for infectious and respiratory diseases. By conducting human challenge clinical trials, the company

    hVIVO plc

    hVIVO Capital Markets Day: Key insights and developments

    hVIVO plc (formerly Open Orphan plc), led by Cathal Friel, is a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials,

    hVIVO plc

    Key differences between Clinical Trials and Clinical Studies

    Understanding the distinction between clinical trials and clinical studies is vital in the realm of medical research. While all clinical trials fall under the broader category of clinical studies, the two are not synonymous. Clinical trials

    hVIVO plc

    The role of healthy volunteers in clinical trials

    Clinical trials are essential in bringing new drugs, treatments, and interventions to market. These trials progress through several phases, with each stage serving a specific purpose. In the early phases, particularly the first phase, healthy volunteers

    hVIVO plc

    What to expect when participating in clinical trials

    When you volunteer for a clinical trial, it’s essential to manage your expectations, understanding both the potential benefits and risks involved. Awareness of the side effects associated with clinical trials can better prepare you for the

    hVIVO plc

    Understanding placebo use in clinical trials

    Various types of clinical trials require participants to help advance medical knowledge, improve patient care, and develop new treatments. A common element in these trials is the use of placebos. Placebos, substances with no therapeutic effect,